What is the therapeutic range for Phenytoin (Dilantin) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Phenytoin Therapeutic Range

The therapeutic range for total serum phenytoin is 10-20 mcg/mL (or 40-80 micromol/L), with free phenytoin levels of 1-2 mcg/mL. 1

Standard Therapeutic Parameters

  • Total serum phenytoin: The FDA-approved therapeutic range is 10-20 mcg/mL, which represents the concentration at which optimum seizure control occurs without clinical signs of toxicity in most patients 1

  • Free phenytoin levels: The therapeutic target for unbound (free) phenytoin is 1-2 mcg/mL 2

  • Timing of level checks: Trough levels should be obtained just prior to the next scheduled dose to assess therapeutic range and patient compliance, while peak levels occur 4-12 hours after oral administration of Dilantin capsules 1

Clinical Context and Individual Variation

While the 10-20 mcg/mL range serves as the standard reference, clinical response must take precedence over numerical targets. The evidence reveals substantial individual variation:

  • Lower effective concentrations: Some patients, particularly those with infrequent primary tonic-clonic seizures, achieve complete seizure control with levels below 10 mcg/mL 3, 4

  • Higher concentrations when needed: Patients with partial epilepsies, complex partial seizures, or higher baseline seizure frequency often require concentrations at the upper end or above 15 mcg/mL for adequate control 4

  • Supratherapeutic levels: In rare cases, patients may require concentrations up to 160 micromol/L (approximately 40 mcg/mL) to control seizures, provided they tolerate these levels without significant toxicity beyond nystagmus 5

Monitoring Strategy After Loading

After IV loading doses (15-18 mg/kg):

  • Therapeutic levels are achieved within 10 minutes of rapid IV infusion completion 2
  • Levels should be checked 2-4 hours after completion to confirm sustained therapeutic concentrations 2
  • Approximately 50% of patients may have subtherapeutic levels at 12 hours post-loading, making this a critical monitoring timepoint 2
  • Most patients (approximately 83%) maintain therapeutic levels at 24 hours after appropriate loading 2

After oral loading doses:

  • Therapeutic levels are generally achieved within 3-8 hours after administration 2
  • Studies show 48-55% of patients achieve therapeutic levels by 3-10 hours post-ingestion 6

Critical Dosing Considerations

  • Steady-state timing: With regular maintenance dosing (without loading), 7-10 days (5-7 half-lives) are required to achieve steady-state levels 1

  • Saturable kinetics: Because phenytoin exhibits Michaelis-Menten (saturable) kinetics at therapeutic concentrations, small dose increases of 10% or more can produce disproportionately large increases in serum levels and potential toxicity 1

  • Dose adjustments: When levels reach 5-10 mcg/mL, subsequent adjustments should be made in small increments of approximately 25 mg rather than the typical 100 mg steps to avoid overshooting the therapeutic range 7

Common Pitfalls

  • Treating numbers instead of patients: In one study, 51% of patients on phenytoin monotherapy achieved complete seizure control at levels either below or above the 10-20 mcg/mL range, emphasizing that clinical judgment supersedes rigid adherence to reference ranges 4

  • Protein binding variations: Since phenytoin is highly protein-bound, free phenytoin levels may be altered in patients with hypoalbuminemia, renal disease, or other conditions affecting protein binding; in these cases, free phenytoin levels provide more accurate assessment 1

  • Premature level checks: Serum levels obtained before steady-state (less than 5-7 half-lives after initiation or dose change) are unreliable for therapeutic decision-making 1

References

Guideline

Monitoring Phenytoin Levels for Optimal Seizure Control

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

How high can we go with phenytoin?

Therapeutic drug monitoring, 2002

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Phenytoin dose adjustment in epileptic patients.

British journal of clinical pharmacology, 1974

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.